An additional fourth dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A predictive model based on data in South-East Asia

Abstract

ABSTRACT Background: The COVID-19 vaccine has been proven to be effective at preventing COVID-19. Usually, the immunization requires two doses. Immunity may begin to wane after receiving all required immunizations. It is typical to administer a second booster dose. The requirement for extra immunizations will be greater in people with preexisting conditions like cancer. However, the need for improved immunity in those with underlying disorders still poses a challenge. Investigating immunogenicity after receiving a second dose of the COVID-19 vaccine is an intriguing topic. Currently, additional immunization doses are advised and used. Several scientists are currently suggesting the use of a vaccine in response to the potential loss of public immunity following routine mass immunization and the potential introduction of a new strain. Several scientists are currently recommending the use of a fourth dosage of the COVID-19 vaccine to some specific immunocompromised groups, like transplant recipients, in view of the likely loss of public immunity following routine mass vaccination and the potential introduction of a new strain. Any research investigating the fourth vaccination’s effectiveness for transplant recipients is intriguing because it is unproven. Method: A clinical model to predict how individual with transplant recipient status will react to the extra-dose of COVID-19 vaccine is done. Results: Based on information that was readily available locally, the authors of this study used a prediction model analysis to analyze the immunogenicity of COVID-19 vaccines made using viral vector and mRNA utilizing a fourth dose for patients with underlying transplant recipient conditions. Conclusion: If a fourth dosage is intended, a variety of mRNA COVID-19 immunization options should be considered.